View More View Less
  • 1 St. Joseph.xx.s Hospital Cancer Institute, Department of Medical Microbiology and Immunology Please ask the editor of the journal.
  • 2 St. Joseph.xx.s Hospital Cancer Institute, Department of Medical Microbiology and Immunology Please ask the editor of the journal.
  • 3 St. Joseph.xx.s Hospital Cancer Institute, Department of Medical Microbiology and Immunology Please ask the editor of the journal.
  • 4 St. Joseph.xx.s Hospital Cancer Institute, Department of Medical Microbiology and Immunology Please ask the editor of the journal.
  • 5 St. Joseph.xx.s Hospital Cancer Institute, Department of Medical Microbiology and Immunology Please ask the editor of the journal.
  • 6 St. Joseph.xx.s Hospital Cancer Institute, Department of Medical Microbiology and Immunology Please ask the editor of the journal.
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $784.00

Biotherapy of malignant diseases has become the fourth treatment modality besides surgery, chemo- and radiotherapy. Whole cell melanoma vaccines with or without BCG and other adjuvants, purified ganglioside and shed antigens, recombinant viruses carrying tumor antigens, dendritic cells pulsed with antigenic peptides etc.are in clinical trials.Efficacious viral oncolysate vaccines induce the host to mount tumor-specific cytotoxic T-cell response and prevention of relapses is supported by clinical trials. The use of „polyvalent” whole cell vaccines vs. purified or genetically engineered single antigen vaccines is justified asi.only very few single tumor antigens are present in all tumors of a given histological type; andii.antigen modulation occurs in tumors rendering them resistant to immune attack generated by vaccine against a single antigen. Thus polyvalent vaccines immunize against several antigens vs.against a selected antigen.

  • Cassel, W. A., Murray, D. R.: A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Med Oncol Tumor Pharmacother 9, 169 (1993).

    'A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. ' () 9 Med Oncol Tumor Pharmacother : 169.

    • Search Google Scholar
  • Sinkovics, J. G.: Complete remissions lasting over three years in adult patients treated for metastatic sarcoma. In Crispen, R. (ed.): Tumor Progression. Elsevier, Amsterdam, New York. 1980. pp. 315-331

    Complete remissions lasting over three years in adult patients treated for metastatic sarcoma , () 315 -331.

    • Search Google Scholar
  • Cassel, W. A., Weidenheim, K. M., Campbell, W. G., Murray, D. R.: Malignant melanoma. Inflammatory mononuclear cell infiltrates in cerebral metastases during concurrent therapy with viral oncolysates. Cancer 57, 1302 (1986).

    'Malignant melanoma. Inflammatory mononuclear cell infiltrates in cerebral metastases during concurrent therapy with viral oncolysates. ' () 57 Cancer : 1302.

    • Search Google Scholar
  • Storkus, W. J., Zeh, H. J., Maeurer, M. J., Salter, R. D., Lotze, M. T.: Identification of human melanoma peptides recognized by Class I restricted tumor infiltrating lymphocytes. J Immunol 151, 3719 (1993).

    'Identification of human melanoma peptides recognized by Class I restricted tumor infiltrating lymphocytes. ' () 151 J Immunol : 3719.

    • Search Google Scholar
  • Bernhardt, H., Jager, E., Maeurer, M. J., Meyer zum Buschenfelds, K. H., Knuth, A.: Tumor associated antigens in human renal cell carcinoma: MHC restricted recognition by cytotoxic T lymphocytes. Tissue Antigens 48, 22 (1996).

    'Tumor associated antigens in human renal cell carcinoma: MHC restricted recognition by cytotoxic T lymphocytes. ' () 48 Tissue Antigens : 22.

    • Search Google Scholar
  • Robbins, P. F., Kawakami, Y.: Human tumor antigens recognized by T cells. Curr Opinion in Immunol 8, 628 (1996).

    'Human tumor antigens recognized by T cells. ' () 8 Curr Opinion in Immunol : 628.

  • Morton, D. L., Foshag, L. J., Hoon, D. S. B., Nizze, J. A., Wanek, L. A., Chang, C., Davtyan, D. G., Gupta, R. K., Elashoff, R., Irie, R. F.: Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 216, 463 (1992).

    'Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. ' () 216 Ann Surg : 463.

    • Search Google Scholar
  • Berd, D., Maguire, H. C., Mastrangelo, M. J.: Treatment of human melanoma with a hapten-modified autologous vaccine. Ann NY Acad Sci 690, 147 (1993).

    'Treatment of human melanoma with a hapten-modified autologous vaccine. ' () 690 Ann NY Acad Sci : 147.

    • Search Google Scholar
  • Lathe, R., Kieny, M. P., Gerlinger, P., Clertant, P., Guizan, I., Cuzin, F., Chambon, P.: Tumour prevention and rejection with recombinant vaccinia. Nature (London) 326, 878 (1987).

    'Tumour prevention and rejection with recombinant vaccinia. ' () 326 Nature (London) : 878.

    • Search Google Scholar
  • Gu, S., Huang, T., Miao, Y., Ruan, L., Zhao, Y., Han, C., Xiao, Y., Zhu, J., Wolf, H.: A preliminary study on the Immunogenicity in rabbits and in human volunteers of a recombinant vaccinia virus expressing Epstein-Barr virus membrane antigen. Chin Med Sci J 6, 241 (1991).

    'A preliminary study on the Immunogenicity in rabbits and in human volunteers of a recombinant vaccinia virus expressing Epstein-Barr virus membrane antigen. ' () 6 Chin Med Sci J : 241.

    • Search Google Scholar
  • Pomer, S., Thiele, R., Stahler, G., Drehmer, I., Lohrke, H., Schirrmacher, V.: Tumor vaccination in renal cell carcinoma with and without interleukin-2 (IL-2) as adjuvant. A clinical contribution to the development of effective active specific immunization. Urologe A 34, 215 (1995).

    'Tumor vaccination in renal cell carcinoma with and without interleukin-2 (IL-2) as adjuvant. A clinical contribution to the development of effective active specific immunization ' () 34 Urologe A : 215.

    • Search Google Scholar
  • Bronte, V., Tsung, K., Rao, J. B., Chen, P. W., Wang, M., Rosenberg, S. A., Restifo, N. P.: IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immunol 154, 5282 (1995).

    'IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. ' () 154 J Immunol : 5282.

    • Search Google Scholar
  • Wallack, M. K., Bash, J. A., Leftheriotis, E., Seigler, H., Bland, K., Wanebo, H., Balch, C., Bartolucci, A. A.: Positive relationship of clinical and serological responses to vaccinia melanoma oncolysates. Arch Surg 122, 1460 (1987).

    'Positive relationship of clinical and serological responses to vaccinia melanoma oncolysates. ' () 122 Arch Surg : 1460.

    • Search Google Scholar
  • Kirchner, H. H., Anton, P., Atzpodien, J.: Adjuvant treatment of locally advanced renal cell cancer with autologous virus-modified tumor vaccines. World J Urol 13, 171 (1995).

    'Adjuvant treatment of locally advanced renal cell cancer with autologous virus-modified tumor vaccines. ' () 13 World J Urol : 171.

    • Search Google Scholar
  • Wallack, M. K., Sivanandham, M., Balch, C. M., Urist, M. M., Bland, K. I., Murray, D., Robinson, W. A., Flaherty, L., Richards, J. M., Bartolucci, A. A., Rosen, L.: Surgical adjuvant active specific immunotherapy for patients with Stage III melanoma: The final analysis of data from a Phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 187, 69 (1998).

    'Surgical adjuvant active specific immunotherapy for patients with Stage III melanoma: The final analysis of data from a Phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. ' () 187 J Am Coll Surg : 69.

    • Search Google Scholar
  • Schirrmacher, V., Ahlert, T., Pröbstle, T., Steiner, H.-H., Herold-Mende, C., Gerhards, R., Hagmüller, E.: Immunization with virus-modified tumor cells. Sem Oncol 25, 677 (1998).

    'Immunization with virus-modified tumor cells. ' () 25 Sem Oncol : 677.

  • Möbus, V., Horn, S., Stöck, M, Schirrmacher, V.: Tumor cell vaccination for gynecological tumors. Hybridoma 12, 543 (1993).

    'Tumor cell vaccination for gynecological tumors. ' () 12 Hybridoma : 543.

  • Schlag, P., Manasterski, M., Gerneth, T., Hohenberger, P., Dueck, M., Herfarth, C., Liebrich, M., Schirrmacher, V.: Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial. Cancer Immunol. Immunother 35, 325 (1992).

    () 35 Cancer Immunol. Immunother : 325.

  • Freedman, R. S., Kouttab, N. M., Bowen, J. M., Edwards, C. L., Katz, R. L.: Lymphokine activity in malignant effusions after intracavity viral oncolysate. Lymphokine Res 8, 115 (1989).

    'Lymphokine activity in malignant effusions after intracavity viral oncolysate. ' () 8 Lymphokine Res : 115.

    • Search Google Scholar
  • Ioannides, C. G., Freedman, R. S., Patenia, R., Bowen, J. M., Ward, N. E., O'Brian, C. A.: Immunological effects of tumor vaccines: III Influenza virus oncolysates inhibit the TPA induced activation of peripheral blood mononuclear cells. In Vivo 5, 1 (1991).

    'Immunological effects of tumor vaccines: III Influenza virus oncolysates inhibit the TPA induced activation of peripheral blood mononuclear cells. ' () 5 In Vivo : 1.

    • Search Google Scholar
  • Ioannides, C. G., Freedman, S. R.: T cell responses to ovarian tumor vaccines: identification and significance for future immunotherapy. Intern Rev Immunol 7, 349 (1991).

    'T cell responses to ovarian tumor vaccines: identification and significance for future immunotherapy. ' () 7 Intern Rev Immunol : 349.

    • Search Google Scholar
  • Matsui, K., Boniface, J. J., Reay, P. A., Schild, H., Fazekas de St. Groth, B., Davis, M. M.: Low affinity interaction of peptide-MHC complexes with T-cell receptors. Science 254, 1788 (1991).

    'Low affinity interaction of peptide-MHC complexes with T-cell receptors. ' () 254 Science : 1788.

    • Search Google Scholar
  • Couderc, B., Zitvogel, L., Douin-Echinard, V., Gjennane, L., Tahara, H., Favre, G., Lotze, M. T., Robbins, P. D.: Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells. Cancer Gene Ther 5, 163 (1998).

    'Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells. ' () 5 Cancer Gene Ther : 163.

    • Search Google Scholar
  • Natali, P. G., Nicotra, M. R., Bigotti, A., Venturo, I., Marcenaro, L., Giacomini, P., Russo, C.: Selective changes in expression of HLA Class I polymorphic determinants in human solid tumors. Proc Natl Acad Sci USA 86, 6719 (1989).

    'Selective changes in expression of HLA Class I polymorphic determinants in human solid tumors. ' () 86 Proc Natl Acad Sci USA : 6719.

    • Search Google Scholar
  • Sinkovics, J. G.: Malignant lymphoma arising from natural killer cells: report of the first case in 1970 and newer developments in the FasL→FasR system. Acta Microbiol Immunol Hung 44, 295 (1997)

    'Malignant lymphoma arising from natural killer cells: report of the first case in 1970 and newer developments in the FasL→FasR system. ' () 44 Acta Microbiol Immunol Hung : 295.

    • Search Google Scholar
  • Ohmori, T., Okada, K., Arita, N., Watanabe, Y., Miyazaki, T., Taberi, R.: Characteristics of MHC antigen expression and tumor-infiltrating mononuclear cells in renal cell adenomas and carcinomas. Histol Histopathol 10, 789 (1995).

    'Characteristics of MHC antigen expression and tumor-infiltrating mononuclear cells in renal cell adenomas and carcinomas. ' () 10 Histol Histopathol : 789.

    • Search Google Scholar
  • Cordon-Cardo, C., Fuks, Z., Drobnjak, M., Moreno, C., Eisenbach, L., Feldman, M.: Expression of HLA-A, B, C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res 51, 6372 (1991).

    'Expression of HLA-A, B, C antigens on primary and metastatic tumor cell populations of human carcinomas. ' () 51 Cancer Res : 6372.

    • Search Google Scholar
  • Zorn, U., Dallmann, I., Grosse, J., Kirchner, H., Poliwoda, H., Atzpodien, J.: Induction of cytokines and cytotoxicity against tumor cells by Newcastle disease virus. Cancer Biother 9, 225 (1994).

    'Induction of cytokines and cytotoxicity against tumor cells by Newcastle disease virus. ' () 9 Cancer Biother : 225.

    • Search Google Scholar
  • von Hoegen, P., Zawatzky, R., Schirrmacher, V.: Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor-specific cytotoxic T-cell activity via induction of interferon alpha/beta. Cell Immunol 126, 80 (1990).

    'Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor-specific cytotoxic T-cell activity via induction of interferon alpha/beta. ' () 126 Cell Immunol : 80.

    • Search Google Scholar
  • Ertel, C., Millar, N. S., Emmerson, P. T., Schirrmacher, V., von Hoegen, P.: Viral hemagglutinin augments peptide-specific T cell responses. Eur J Immunol 23, 2592 (1993).

    'Viral hemagglutinin augments peptide-specific T cell responses. ' () 23 Eur J Immunol : 2592.

    • Search Google Scholar
  • Ten, R. M., Blank, V., Le Bail, O., Kourilsky, P., Israel, A.: Two factors IRF1 and KNF1/NF-kappa B, cooperate during induction of MHC class 1 gene expression by interferon alpha, beta or Newcastle disease virus. C. R. Acad Sci III 316, 496 (1993).

    'Two factors IRF1 and KNF1/NF-kappa B, cooperate during induction of MHC class 1 gene expression by interferon alpha, beta or Newcastle disease virus. ' () 316 C. R. Acad Sci III : 496.

    • Search Google Scholar
  • Sinkovics, J. G.: Viral oncolysates as human tumor vaccines. Intern Rev Immunol 7, 259 (1991)

    'Viral oncolysates as human tumor vaccines. ' () 7 Intern Rev Immunol : 259.

  • Ferrone, S., Marincola, F. M.: Loss of HLA class I antigens by melanoma cells: molecular mechanism, functional significance and clinical relevance. Immunol Today 16, 487 (1995).

    'Loss of HLA class I antigens by melanoma cells: molecular mechanism, functional significance and clinical relevance ' () 16 Immunol Today : 487.

    • Search Google Scholar
  • Kiessling, R., Kono, K., Petersson, M., Wasserman, K.: Immunosuppression in human tumor-host interaction: role of cytokines and alterations in signal-transducing molecules. Springer Semin Immunopathol 18, 227 (1996).

    'Immunosuppression in human tumor-host interaction: role of cytokines and alterations in signal-transducing molecules ' () 18 Springer Semin Immunopathol : 227.

    • Search Google Scholar
  • Mitchell, M. S., Kan-Mitchell, J., Kempf, R. A., Harel, W., Shau, H., Lind, S.: Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 48, 5883 (1988).

    'Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant ' () 48 Cancer Res : 5883.

    • Search Google Scholar
  • Lupetti, R., Pisarra, P., Verrecchia, A., Farina, C., Nicolini, G., Anichini, A., Bordignon, C., Sensi, M., Parmiani, G., Traversari, C.: Translation of a retained intron in tyrosinase-related-protein (TRP)2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanoma lineage. J Exp Med 188, 1005 (1998).

    'Translation of a retained intron in tyrosinase-related-protein (TRP)2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanoma lineage. ' () 188 J Exp Med : 1005.

    • Search Google Scholar
  • Vierboom, M. P., Nijman, H. W., Offringa, R., van der Voort, E. I., van Hall, T., van der Broek, L., Fleuren, G. J., Kenemans, P., Kast, W. M., Melief, C. J.: Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med 186, 695 (1997).

    'Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. ' () 186 J Exp Med : 695.

    • Search Google Scholar
  • Van Pel, A., van der Bruggen, P., Coulie, P. G., Brichard, V. G., Lethe, B., van den Eynde, B., Uyttenhove, C., Renauld, J. C., Boon, T.: Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunology Rev 145, 229 (1995).

    'Genes coding for tumor antigens recognized by cytolytic T lymphocytes. ' () 145 Immunology Rev : 229.

    • Search Google Scholar
  • Rosenberg, S. A., Kawakami, Y., Robbins, P. F., Wang, R. F.: Identification of genes encoding cancer antigens: implications for cancer immunotherapy. Adv Cancer Res 70, 145 (1996).

    'Identification of genes encoding cancer antigens: implications for cancer immunotherapy. ' () 70 Adv Cancer Res : 145.

    • Search Google Scholar
  • Marincola, F. M., Shamamian, P., Alexander, R. B., Gnarra, J. R., Turetskaya, R. L., Nedospasov, S. A., Simonis, T. B., Taubenberger, J. K., Yannelli, J., Mixon, A., Restifo, N. P., Herlyn, M., Rosenberg, S. A.: Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J Immunol 153, 1225 (1994).

    'Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. ' () 153 J Immunol : 1225.

    • Search Google Scholar
  • Sinkovics, J., Horvath, J., Horak, A.: Lymphocytes cytotoxic to human tumor cells. In Rao, R. S., Deo, M. G., Sanghvi, L. D., Mittra, I. (eds): Proceedings of the XVI International Cancer Congress. Bologna, Italy, 1994. pp. 93-102

    'Lymphocytes cytotoxic to human tumor cells ' , , .

  • Luboldt, H. J., Kubens, B. S., Rubben, H., Grosse-Wilde, H.: Selective loss of human leukocyte antigen class I allele expression in advanced renal cell carcinoma. Cancer Res 56, 826 (1996).

    'Selective loss of human leukocyte antigen class I allele expression in advanced renal cell carcinoma. ' () 56 Cancer Res : 826.

    • Search Google Scholar
  • Restifo, N. R., Marincola, F. M., Kawakami, Y., Taubenberger, J., Yannelli, J. R., Rosenberg, S. A.: Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. JNCI 88, 100 (1996).

    'Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. ' () 88 JNCI : 100.

    • Search Google Scholar
  • Maeurer, M. J., Gollin, S. M., Storkus, W. J., Swaney, W., Karbach, J., Martin, D., Castelli, C., Salter, R., Knuth, A., Lotze, M. T.: Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6. Clin Cancer Res. 2, 641 (1996).

    'Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6. ' () 2 Clin Cancer Res. : 641.

    • Search Google Scholar
  • Everson, M. P., Lemak, D. G., McDuffie, D. S., Koopman, W. J., McGhee, J. R., Begley, W. W.: Dendritic cells from Peyer's patch and spleen induce different T helper cell responses. J. Interferon Cytokine Res 18, 103 (1998).

    'Dendritic cells from Peyer's patch and spleen induce different T helper cell responses. ' () 18 J. Interferon Cytokine Res : 103.

    • Search Google Scholar
  • Michell, M. S., Harel, W., Kan-Mitchell, J., LeMay, L. G., Goedegebuure, P., Hang, X. Q., Hoffman, F., Groshen, S.: Active specific immunotherapy of melanoma with allogeneic cell lysates. Rational, results, and possible mechanisms of action. Ann N Y Acad Sci 690, 153 (1993).

    'Active specific immunotherapy of melanoma with allogeneic cell lysates. Rational, results, and possible mechanisms of action. ' () 690 Ann N Y Acad Sci : 153.

    • Search Google Scholar
  • Mitchell, M. S., Jakowitz, J., Harel, W., Dean, G., Stevenson, L., Boswell, W. D., Groshen, S.: Increased effectiveness of interferon alpha-2B following active specific immunotherapy for melanoma. J Clin Oncol 12, 402 (1994).

    'Increased effectiveness of interferon alpha-2B following active specific immunotherapy for melanoma. ' () 12 J Clin Oncol : 402.

    • Search Google Scholar
  • Mitchell, M. S., Liggett, P. E., Kan-Mitcell, J., Murphree, A. L., Dean, G., Spears, L., Walonker, F.: Sustained regression of a primary choroidal melanoma under the influence of a therapeutic melanoma vaccine. J Clin Oncol 12, 396 (1994).

    'Sustained regression of a primary choroidal melanoma under the influence of a therapeutic melanoma vaccine. ' () 12 J Clin Oncol : 396.

    • Search Google Scholar
  • von Eschen, K. B., Mitchell, M. S.: Phase III trial of melacine melanoma therracine versus combination chemotherapy in the treatment of stage IV melanoma. Oral abstracts of the 4th World Confence on Melanoma. Melanoma Res 7, S51 (1997).

    'Phase III trial of melacine melanoma therracine versus combination chemotherapy in the treatment of stage IV melanoma. Oral abstracts of the 4th World Confence on Melanoma. ' () 7 Melanoma Res : S51.

    • Search Google Scholar
  • Sinkovics, J. G., Plager, C., McMurray, M. J.: Chemoimmunotherapy: basic principles and clinical examples, Adv Med Oncol, Research and Education (M. Moore, ed.) Oxford, New York: Pergamon Press 6, 121 (1979).

    Chemoimmunotherapy: basic principles and clinical examples, Adv Med Oncol, Research and Education , () 121.

    • Search Google Scholar
  • Berd, D., Maguire, H. C., Schuchter, L. M., Hamilton, R., Hauck, W. W., Sato, T., Mastrangelo, M. J.: Autologus hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol 15, 2359 (1997).

    'Autologus hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. ' () 15 J Clin Oncol : 2359.

    • Search Google Scholar
  • Sensi, M., Farina, C., Maccalli, C., Anichini, A., Berd, D., Parmiani, G.: Intralesional selection of T cell clonotypes in the immune response to melanoma antigens occurring during vaccination. J Immunother 21, 198 (1998).

    'Intralesional selection of T cell clonotypes in the immune response to melanoma antigens occurring during vaccination. ' () 21 J Immunother : 198.

    • Search Google Scholar
  • Kageshita, T., Hirai, S., Ono, T., Ferrone, S.: Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic MAb MK2-23. Immunohistochemical analysis of the reactivity of anti-idiotypic MAb with surgically removed melanoma lesions. Int J Cancer 6, 334 (1995).

    'Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic MAb MK2-23. Immunohistochemical analysis of the reactivity of anti-idiotypic MAb with surgically removed melanoma lesions. ' () 6 Int J Cancer : 334.

    • Search Google Scholar
  • Sharma, S., Miller, P. W., Stolina, M., Zhu, L., Huang, M., Paul, R. W., Dubinett, S. M.: Multicomponent gene therapy vaccines for lung cancer: effective eradication of established murine tumors in vivo with interleukin-7/herpes simplex thymidine kinase-transduced autologous tumor and ex vivo activated dendritic cells. Gene Ther 4, 1361 (1997).

    'Multicomponent gene therapy vaccines for lung cancer: effective eradication of established murine tumors in vivo with interleukin-7/herpes simplex thymidine kinase-transduced autologous tumor and ex vivo activated dendritic cells. ' () 4 Gene Ther : 1361.

    • Search Google Scholar
  • Abdel-Wahab, Z., Weltz, C., Hester, D., Pickett, N., Vervaert, C., Barber, J. R., Jolly, D, Seigler, H. F.: A Phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: monitoring the humoral immune response. Cancer 80, 401 (1997).

    'A Phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: monitoring the humoral immune response. ' () 80 Cancer : 401.

    • Search Google Scholar
  • Elder, E. M., Lotze, M. T., Whiteside, T. L.: Successful culture and selection of cytokine gene-modified human dermal fibroblasts for the biological therapy of patients with cancer. Hum Gene Ther 7, 479 (1996).

    'Successful culture and selection of cytokine gene-modified human dermal fibroblasts for the biological therapy of patients with cancer. ' () 7 Hum Gene Ther : 479.

    • Search Google Scholar
  • McArthur, J. G., Mulligan, R. C.: Induction of protective anti-tumor immunity by gene-modified dendritic cells. J Immunother 21, 44 (1998).

    'Induction of protective anti-tumor immunity by gene-modified dendritic cells. ' () 21 J Immunother : 44.

    • Search Google Scholar
  • Tuting, T., DeLeo, A. B., Lotze, M. T., Storkus, W. J.: Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo. Eur J Immunol 27, 2702 (1997).

    'Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo. ' () 27 Eur J Immunol : 2702.

    • Search Google Scholar
  • Miller, K., Abeles, G., Oratz, R., Zeleniuch-Jacquotte, A., Cui, J., Roses, D. F., Harris, M. N., Bystrin, J-C.: Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine. Cancer 75, 495 (1995).

    'Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine. ' () 75 Cancer : 495.

    • Search Google Scholar
  • Bystryn, J-C., Henn, M., Li, J., Shroba, S.: Identification of immunogenic human melanoma antigens in a polyvalent melanoma vaccine. Cancer Res 52, 5948 (1992).

    'Identification of immunogenic human melanoma antigens in a polyvalent melanoma vaccine. ' () 52 Cancer Res : 5948.

    • Search Google Scholar
  • Chu, J. W., Sharom, F.J: Gangliosides inhibit T-lymphocyte proliferation by preventing the interaction of interleukin-2 with its cell surface receptors. Immunol 79, 10 (1993).

    'Gangliosides inhibit T-lymphocyte proliferation by preventing the interaction of interleukin-2 with its cell surface receptors. ' () 79 Immunol : 10.

    • Search Google Scholar
  • Helling, F., Zhang, S., Shang, A., Adluri, S., Calves, M., Koganty, R., Longenecker, B. M., Yao, T. J., Oettgen, H. F., Livingston, P. O.: GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 55, 2785 (1995).

    'GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. ' () 55 Cancer Res : 2785.

    • Search Google Scholar
  • Ritter, G., Ritter-Boosfeld, E., Adluri, R., Calves, M., Ren, S., Yu, R. R., Oettgen, H. F., Old, L. J., Livingston, P. O.: Analysis of the antibody response to immunization with purified O-acetyl GD3 gangliozides in patients with malignant melanoma. Int J Cancer 62, 668 (1995).

    'Analysis of the antibody response to immunization with purified O-acetyl GD3 gangliozides in patients with malignant melanoma. ' () 62 Int J Cancer : 668.

    • Search Google Scholar
  • Livingston, P. O., Zhang, S., Adluri, S., Yao, T. J., Graeber, L., Ragupathi, G., Helling, F., Fleisher, M.: Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is increased by IgG antibodies. Cancer Immunol Immunother 43, 324 (1997).

    'Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is increased by IgG antibodies. ' () 43 Cancer Immunol Immunother : 324.

    • Search Google Scholar
  • Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., Wunderlich, J. R., Parkhurst, M. R., Kawakami, Y., Seipp, C. A., Einhorn, J. H., White, D. E.: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4, 321 (1998).

    'Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. ' () 4 Nat Med : 321.

    • Search Google Scholar
  • Gong, J., Chen, D., Kishiwaba, M., Kufe, D.: Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nature Medicine 3, 558 (1997).

    'Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. ' () 3 Nature Medicine : 558.

    • Search Google Scholar
  • Nair, S. K., Snyder, D., Rouse, B. T., Gilboa, E.: Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer 70, 706 (1997).

    'Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. ' () 70 Int J Cancer : 706.

    • Search Google Scholar
  • Nestle, O. F., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., Schadendorf, D.: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Medicine 4, 328 (1998).

    'Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. ' () 4 Nature Medicine : 328.

    • Search Google Scholar
  • Earl, P. L., Moss, B., Morrison, R. P., Wehrly, J., Nishio, J., Chesebro, B.: T-lymphocyte priming and protection against Friend leukemia by vaccina-retrovirus env gene recombinant. Science 234, 728 (1986).

    'T-lymphocyte priming and protection against Friend leukemia by vaccina-retrovirus env gene recombinant. ' () 234 Science : 728.

    • Search Google Scholar
  • Hu, Sh-L., Plowman, G. D., Sridhar, P., Stevenson, U. S., Brown, J. P., Estin, C. D.: Characterization of a recombinant vaccinia virus expressing human melanoma-associated antigen p97. J Virol 62, 176 (1988).

    'Characterization of a recombinant vaccinia virus expressing human melanoma-associated antigen p97. ' () 62 J Virol : 176.

    • Search Google Scholar
  • Mandl, S., Sigal, L. J., Rock, K. L., Andino, R.: Poliovirus vaccine vectors elicit antigen-specific cytotoxic T cells and protect against lethal challenge with malignant melanoma cells expressing a model antigen. PNAS 95, 8216 (1998).

    'Poliovirus vaccine vectors elicit antigen-specific cytotoxic T cells and protect against lethal challenge with malignant melanoma cells expressing a model antigen. ' () 95 PNAS : 8216.

    • Search Google Scholar
  • Roth, J., Dittmer, D., Rea, D., Tartaglia, J., Paoletti, E., Levine, A. J.: p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. PNAS 93, 4781 (1996).

    'p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. ' () 93 PNAS : 4781.

    • Search Google Scholar
  • Fong, I., Ruegg, C. L., Brockstedt, D., Engelman, E. G., Laus, R.: Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J Immunol 159, 3113 (1997).

    'Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. ' () 159 J Immunol : 3113.

    • Search Google Scholar
  • Boursnell, M. E., Rutherford, E., Hickling, J. K., Rollinson, E. A., Munro, A. J., Rolley, N., McLean, C. S., Borysiewicz, L. K., Vousden, K., Inglis, S. C.: Construction and characterization of a recombinant vaccinia virus expressing papillomavirus proteins for immunotherapy of cervical cancer. Vaccine 14, 1485 (1996).

    'Construction and characterization of a recombinant vaccinia virus expressing papillomavirus proteins for immunotherapy of cervical cancer. ' () 14 Vaccine : 1485.

    • Search Google Scholar
  • Hariharan, K., Braslawsky, G., Barnett, R. S., Berquist, L. G., Huynh, T., Hanna, N., Black, A.: Tumor regression in mice following vaccination with human papillomavirus E7 recombinant protein in PROVAX. Int J Oncol 12, 1229 (1998).

    'Tumor regression in mice following vaccination with human papillomavirus E7 recombinant protein in PROVAX. ' () 12 Int J Oncol : 1229.

    • Search Google Scholar
  • Borysiewicz, L. K., Fiander, A., Nimoako, M., Wilkinson, G. W., Westmoreland, D., Evans, A. S., Adams, M., Stacey, S. N., Boursnell, M. E., Rutherford, E., Hickling, J. K., Inglish, S. C.: A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347, 1523 (1996).

    'A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. ' () 347 Lancet : 1523.

    • Search Google Scholar
  • Jaffe, E. M., Dranoff, G., Cohen, L. K. L., Hauda, K. M., Clif, S., Marshall, F. F., Mulligan, R. C., Pardoll, D. M.: High efficiency gene transfer into primary human tumor explants without cell selection. Cancer Res 53, 2221 (1993).

    'High efficiency gene transfer into primary human tumor explants without cell selection. ' () 53 Cancer Res : 2221.

    • Search Google Scholar
  • Schweighoffer, T., Berger, M., Buschle, M., Schmidt, W., Birnstiel, M. L.: Adenovirus-enhanced receptor-mediated transferrinfection for the generation of tumor vaccines. Cytokines Mol Ther 2, 185 (1996).

    'Adenovirus-enhanced receptor-mediated transferrinfection for the generation of tumor vaccines. ' () 2 Cytokines Mol Ther : 185.

    • Search Google Scholar
  • Hodge, J. W., Schlom, J., Donohue, S. J., Tomaszewski, J. E., Wheeler, C. W., Levine, B. S., Gritz, L., Panicali, D., Kantor, J. A.: A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate. Int J Cancer 63, 231 (1995).

    'A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate. ' () 63 Int J Cancer : 231.

    • Search Google Scholar
  • Irvin, K. R., Chamberlain, R. S., Shulman, E. P., Surman, D. R., Rosenberg, S. A., Restifo, N. P.: Enhancing efficacy of recombinant anticancer vaccines with prime/boost regiment that use two different vectors. J Natl Cancer Inst 89, 1595 (1997).

    'Enhancing efficacy of recombinant anticancer vaccines with prime/boost regiment that use two different vectors. ' () 89 J Natl Cancer Inst : 1595.

    • Search Google Scholar
  • Donnelly, J. J., Ulmer, J. B., Shiver, J. W., Liu, M. A.: DNA vaccines. Ann Review Immunol 15, 617 (1997).

    'DNA vaccines. ' () 15 Ann Review Immunol : 617.

  • Mahvi, D. M., Sheehy, M. J., Yang, N. S.: DNA cancer vaccines: a gene gun approach. Immunol Cell Biol 75, 456 (1997).

    'DNA cancer vaccines: a gene gun approach. ' () 75 Immunol Cell Biol : 456.

  • Stopeck, A. T., Hersh, E., Akporiaye, E. T., Harris, D. T., Grogan, T., Unger, E., Warneke, J., Schluter, S. F., Stahl, S.: Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncol 15, 341 (1997).

    'Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. ' () 15 J Clin Oncol : 341.

    • Search Google Scholar
  • Waddill, W., Wright, W., Unger, E., Stopeck, A. T., Akporiaye, E., Harris, D., Grogan, T., Schluter, S., Hersh, E., Stahl, S.: Human gene therapy for melanoma: CT guided interstitial injection. AJR Am J Roentgenol 169, 63 (1997).

    'Human gene therapy for melanoma: CT guided interstitial injection. ' () 169 AJR Am J Roentgenol : 63.

    • Search Google Scholar
  • Lindenmann, J., Klein, P.: Immunological aspects of viral oncolysis. Recent Results Cancer Res 9, 1 (1967).

    'Immunological aspects of viral oncolysis. ' () 9 Recent Results Cancer Res : 1.

  • Koprowski, H., Love, R., Koprowska, I.: Viruses and tumor growth. Tex Rep Biol Med 15, 111 (1957).

    'Viruses and tumor growth. ' () 15 Tex Rep Biol Med : 111.

  • Strand, S., Hofmann, W. J., Hug, H., Muller, M., Otto, G., Strand, D., Mariani, S. M., Stremmel, W., Krammer, P. H., Galle, P. R.: Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - A mechanism of immune evasion? Nature Med 2, 1361 (1996).

    'Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - A mechanism of immune evasion? ' () 2 Nature Med : 1361.

    • Search Google Scholar
  • Niehans, G. A., Brunner, T., Frizelle, S. P., Liston, J. C., Salerno, C. T., Knapp, D. J., Green, D. R., Kratzke, R. A.: Human lung carcinomas express Fas ligand. Cancer Res., 57, 1007 (1997).

    'Human lung carcinomas express Fas ligand. ' () 57 Cancer Res. : 1007.

  • Rivoltini, L., Radrizzani, M., Accornero, P., Squarcina, P., Chiodoni, C., Mazzocchi, A., Castelli, C., Tarsini, P., Viggiano, V., Belli, F., Colombo, M. P., Parmiani, G.: Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing. J Immunol 161, 1220 (1998).

    'Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing. ' () 161 J Immunol : 1220.

    • Search Google Scholar
  • Collins, P. L., Hightower, L. E.: Newcastle disease virus stimulates the cellular accumulation of stress (heat shock) mRNAs and proteins. J Virol 44, 703 (1982).

    'Newcastle disease virus stimulates the cellular accumulation of stress (heat shock) mRNAs and proteins. ' () 44 J Virol : 703.

    • Search Google Scholar
  • Edgington, S. M.: Therapeutic applications of heat shock proteins. Biotechnology 13, 1442 (1995)

    'Therapeutic applications of heat shock proteins. ' () 13 Biotechnology : 1442.

  • Pardoll, D. M.: Cancer vaccines. Nat Med 4(5 Suppl.), 525 (1998)

    'Cancer vaccines. ' () 4 Nat Med : 525.

  • Reichard, K. W., Lorence, R. M., Cascino, C. J., Peeples, M. E., Walter, R. J., Fernando, M. B., Reyes, H. M., Greager, J. A.: Newcastle disease virus selectively kills human tumor cells. J Surg Res 52, 448 (1992).

    'Newcastle disease virus selectively kills human tumor cells. ' () 52 J Surg Res : 448.

  • Bar-Eli, N., Giloh, H., Schlesinger, M., Zakay-Rones, Z.: Preferential cytotoxic effect of Newcastle disease virus on lymphoma cells. J Cancer Res Clin Oncol 122, 409 (1996).

    'Preferential cytotoxic effect of Newcastle disease virus on lymphoma cells. ' () 122 J Cancer Res Clin Oncol : 409.

    • Search Google Scholar
  • Lorence, R. M., Katubig, B. B., Reichard, K. W., Phuangsab, A., Sassetti, M. D., Walter, R. J., Peeples, M. E.: Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Cancer Res 54, 6017 (1994).

    'Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. ' () 54 Cancer Res : 6017.

    • Search Google Scholar
  • Sinkovics, J. G., Plager, C., McMurray, M., Papadopoulos, N. E., Waldinger, R., Combs, S., Romero, J. J., Romsdahl, M. M.: Adjuvant chemo immunotherapy for malignant melanoma. In Crispen, R. (ed.): Neoplasm Immunity: Experimental and Clinical. Elsevier North Holland, New York, Amsterdam. 1980. pp. 481-519

    Adjuvant chemo immunotherapy for malignant melanoma , () 481 -519.

  • Sinkovics, J. G., Papadopoulos, N. E., Plager, C.: Viral oncolysates for the immunotherapy of human tumors. In Yohn, D. S., Blakeslee, J. J. (eds): Proceedings of the 10th International Symposium for Comparative Research on Leukemia and Related Diseases. Elsevier BioMed, New York, Amsterdam. 1981. pp. 613-615

    Viral oncolysates for the immunotherapy of human tumors 613 615

  • Sinkovics, J. G.: Immunotherapy with viral oncolysates for sarcoma. JAMA 237, 869 (1977).

    'Immunotherapy with viral oncolysates for sarcoma ' () 237 JAMA : 869.

  • Hou, S., Mo, X. T., Hyland, L., Doherty, P. C.: Host response to Sendai virus in mice lacking class II major histocompatibility complex glycoproteins. J Virol 69, 1429 (1995).

    'Host response to Sendai virus in mice lacking class II major histocompatibility complex glycoproteins. ' () 69 J Virol : 1429.

    • Search Google Scholar
  • Umansky, V., Shatrov, V. A., Lehmann, V., Schirrmacher, V.: Induction of NO synthesis in macrophages by Newcastle disease virus is associated with activation of nuclear factor-kappa B. Int Immunol 8, 491 (1996).

    'Induction of NO synthesis in macrophages by Newcastle disease virus is associated with activation of nuclear factor-kappa B. ' () 8 Int Immunol : 491.

    • Search Google Scholar
  • Hock, H., Dorsch, M., Kunzendorf, U., Berla, K., Qin, Zh., Diamantstein, T., Blankenstein, T.: Vaccination with tumor cells genetically engineered to produce different cytokines: Effectivity not superior to a classical adjuvant. Cancer Res 53, 714 (1993).

    'Vaccination with tumor cells genetically engineered to produce different cytokines: Effectivity not superior to a classical adjuvant. ' () 53 Cancer Res : 714.

    • Search Google Scholar
  • Gu, X. G., Schmitt, M., Hiasa, A., Nagata, Y., Ikeda, H., Sasaki, Y., Akiyoshi, K., Sunamoto, J., Nakamura, H., Kuribayashi, K., Shiku, H.: A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune responses against HER2-expressing murine sarcomas. Cancer Res 58, 3385 (1998).

    'A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune responses against HER2-expressing murine sarcomas. ' () 58 Cancer Res : 3385.

    • Search Google Scholar
  • Hariharan, K., Braslawsky, G., Barnett, R. S., Berquist, L. G., Huynh, T., Hanna, N., Black, A.: Tumor regression in mice following vaccination with human papillomavirus E7 recombinant protein in PROVAX. Int J Oncol 12, 1229 (1998).

    'Tumor regression in mice following vaccination with human papillomavirus E7 recombinant protein in PROVAX. ' () 12 Int J Oncol : 1229.

    • Search Google Scholar
  • McLaughlin, J. P., Schlom, J., Kantor, J. A., Greiner, J. W.: Improved immunotherapy of a recombinant carcinoembryonic antigen vaccine when given in combination with interleukin-2. Cancer Res 56, 2361 (1996).

    'Improved immunotherapy of a recombinant carcinoembryonic antigen vaccine when given in combination with interleukin-2. ' () 56 Cancer Res : 2361.

    • Search Google Scholar
  • Kirchner, H. H., Anton, P., Atzpodien, J.: Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccine. World J Urol 13, 171 (1995).

    'Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccine. ' () 13 World J Urol : 171.

    • Search Google Scholar
  • Payvandi, F., Amrute, S., Fitzgerald-Bocarsaly, P.: Exogenous and endogenous IL-10 regulate IFN production by peripheral blood mononuclear cells in response to viral stimulation. J Immunol 160, 5861 (1998).

    'Exogenous and endogenous IL-10 regulate IFN production by peripheral blood mononuclear cells in response to viral stimulation. ' () 160 J Immunol : 5861.

    • Search Google Scholar
  • Mottonen, M., Isomaki, P., Saario, R., Toivanen, P., Punnonen, J., Lassila, O.: Interleukin-10 inhibits the capacity of synmovial macrophages to function as antigen-presenting cells. Br J Rheumat 37, 1207 (1998).

    'Interleukin-10 inhibits the capacity of synmovial macrophages to function as antigen-presenting cells. ' () 37 Br J Rheumat : 1207.

    • Search Google Scholar
  • Schwartz, R., Momburg, F., Moldenhauer, G., Dorken, B., Schirrmacher, V.: Induction of HLA class-II antigen expression on human carcinoma cell lines by IFN-gamma. Int J Cancer 35, 245 (1985).

    'Induction of HLA class-II antigen expression on human carcinoma cell lines by IFN-gamma. ' () 35 Int J Cancer : 245.

    • Search Google Scholar
  • Lee, R. K., Spielman, J., Zhao, D. Y., Olsen, K. J., Podack, E. R.: Perforin, Fas ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells. J Immunol 157, 1919 (1996).

    'Perforin, Fas ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells. ' () 157 J Immunol : 1919.

    • Search Google Scholar
  • Sinkovics, J. G., Thota, H., Kay, H. D., Loh, K. K., Williams, D. E., Howe, C. D., Schullenberger, C. C.: Intensification of immune reactions by immunotherapy. Attempts at measuring sarcoma-specific reactions in vitro. In: Crispen, R. G. (ed.): Neoplasm Immunity: Theory and Application. Evanston, University of Illinois Press, 1974. pp. 137-152

    Intensification of immune reactions by immunotherapy. Attempts at measuring sarcoma-specific reactions in vitro , () 137 -152.

    • Search Google Scholar
  • Sinkovics, JG, Plager, C, Romero, J. J.: Immunology and immunotherapy of patients with sarcomas. In Crispen, R. (ed.): 1977 Chicago Symposium: Immunotherapy of Solid Tumors. Franklin Institute Press, Philadelphia PA. 1977. pp. 211-219

    'Immunology and immunotherapy of patients with sarcomas ' , , .

  • O'Connell, J., O'Sullivan, G. C., Collins, K., Shanahan, F.: The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184, 1075 (1996).

    'The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. ' () 184 J Exp Med : 1075.

    • Search Google Scholar
  • Hahne, M., Rimaldi, D., Schroter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., Carottini, J., Tachopp, J.: Melanoma cell expression of Fas(APO-1/CD95) ligand: implication for tumor immune escape. Science 274, 1363 (1996).

    'Melanoma cell expression of Fas(APO-1/CD95) ligand: implication for tumor immune escape. ' () 274 Science : 1363.

    • Search Google Scholar

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Nov 2020 0 0 0
Dec 2020 0 0 0
Jan 2021 1 0 0
Feb 2021 0 0 0
Mar 2021 6 0 0
Apr 2021 0 0 0
May 2021 0 0 0